Trial intelligence / Profile preview

Andamertinib versus platinum-doublet chemotherapy in treatment-naive advanced non-squamous NSCLC with EGFR PACC or L861Q mutations

CTR20254906Phase 2Active

Sponsor

Anshi Pharma

Start

Mar 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1